Pharmacovigilance System Master File: An Overview of Changes in the EAEU Good Pharmacovigilance Practice

The development of international regulatory practices and the accumulation of new experience in pharmacovigi­lance prompted the need to amend the Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union (EAEU GVP Guideline), first adopted in 2016.The aim of the study was to review, from a regulatory expert’s perspective, the changes to the structure and presentation of the pharmacovigilance system master file (PSMF) introduced with the amendment of the EAEU GVP Guideline effective since December 6, 2022.The authors compared the requirements for the PSMF outlined in the new edition of the EAEU GVP Guideline adopted by Decision No.81 of the Council of the Eurasian Economic Commission of 19.06.2022 “On Amendments to the Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union” with the requirements described in the previous version of this document.The structure and content of Module III, Pharmacovigilance System Master File, have been significantly amended in the new version of the EAEU GVP Guideline; this will require marketing authorisation holders (MAHs) to revise the PSMFs describing pharmacovigilance system data. The most significant editorial changes have been made to the paragraphs concerning the PSMF format, the pharmacovigilance quality system, and the presentation of information in the Annexes. The amendment has strengthened the control of records and documentation related to the pharmacovigilance system. Electronic PSMFs are acceptable; electronic book-marking and searchable text make working with the PSMF more convenient for representatives of MAHs and experts of regulatory authorities. Aligning of the PSMF with the requirements of the new edition of the EAEU GVP Guideline will contribute to improving the pharmacovigilance system operation and performance

Analysis of the Causes for Renal Dysfunction during Antibiotic Therapy in a Patient with Lyme Disease

Adverse drug reactions (ADRs) are recorded throughout the lifecycle of a medicinal product. In the post-marketing period, new ADRs are primarily identified via drug safety signals. In order to assess a signal and establish causality between an adverse drug reaction and a suspected medicinal product, it is necessary to evaluate the signal strength and quality.The aim of the study was to analyse the information submitted to Russian regulatory authorities by a patient and check it for a potential causal association of acute tubulointerstitial nephritis (ATIN) with the use of ceftriaxone and with the patient’s principal diagnosis, Lyme disease.Materials and methods: the authors analysed the patient’s submission received by the Ministry of Health of the Russian Federation in 2022 with a complaint that the treatment of Lyme disease with ceftriaxone had caused ATIN. The probability of a causal relationship between the medicinal product and the ADR was evaluated using the Naranjo algorithm.Results: according to the review of literature and the spontaneous reports collected in Pharmacovigilance 2.0, the database in the Automated Information System of the Russian Federal Service for Surveillance in Healthcare, both ceftriaxone and the underlying condition (Lyme disease) may cause renal abnormalities. Ceftriaxone is potentially nephrotoxic; it mainly affects the tubular system of the kidneys. Borreliosis may cause kidney damage as well; such damage manifests clinically as rapidly progressing and fatal damage to the glomeruli.Conclusions: the probability of a causal relationship between the development of ATIN in the complainant and the use of ceftriaxone was categorised as “possible”. However, the information available did not allow for establishing a definite relationship between kidney damage and the use of the medicinal product. Further monitoring of similar cases is necessary to minimise the risks of developing this pathology during treatment with ceftriaxone

Results of Modeling Experiments in Designing Immuno-Enzyme Test-System for the Detection of Antibodies to <I>Yersinia pestis</I> F1 (ELISA-Ab-F1 <I>Yersinia pestis</I>)

Designed is immuno-enzyme test-system for the detection of antibodies to Yersinia pestis capsular antigen F1 – “ELISA-Ab-F1 Yersinia pestis”. On the model of laboratory mice it is demonstrated that this test-system is highly specific, its diagnostic titer being 1/320.Diagnostic value of the test-system is 83.3–88.9 % as revealed through investigations of sera and blood suspension samples, swabs of thoracic organs of animals, inoculated with live plague vaccine, strains of plague microbe, containing and deprived of pFra, as well as with heterologous bacteria

ISOLATION OF GLICOPROTEID FROM THE FIXED RABIES VIRUS, STRAIN «MOSCOW 3253», AND CONSTRUCTING OF DOT-IMMUNOASSAY DIAGNOSTICUM ON ITS BASIS

Described here are the results of glicoproteid isolation from the fixed rabies virus, strain «Moscow 3253», using non-ionic detergent with subsequent chromatographic purification. The obtained antigen was demonstrated to be applicable as immunoreagent for construction of diagnosticum, by means of conjugation with colloid gold nanoparticles. The diagnosticum is meant for detection of specific antibodies in immune sera of horsesproducers, and in the preparation of anti-rabies immunoglobulin, in dot-immunoassay

Constructing and Medical Trials of a Monoclonal Dot-Immuno-Enzyme Test-System “DIATul-M” for Tularemia Microbe Detection

mc/ml. Additionally, this test-system has been proving for acquisition of sustainable results after 6 months of storing (the observation period). Medical trials of the panel of reagents “Monoclonal dot-immuno-enzyme test-system for tularemia microbe detection” have shown it to be a prospective preparation for implementation into the national healthcare practices both under stationary and field conditions

Обоснование методических подходов к экспертной оценке подлинности биомедицинских клеточных продуктов

The manufacturer (developer) has to prepare a specification for each newly developed biomedical cell product (BCP) that has passed the stage of preclinical studies. The specification is included into the registration dossier when applying for marketing authorisation of a BCP. In accordance with the Order of the Ministry of Health of the Russian Federation No. 14n of 19 January 2017 «On approval of the specification format for a biomedical cell product» the specification should contain information about authenticity of the cell line used in the BCP, namely: morphological characteristics, expression of specific markers, expression of specific genes, expression of specific proteins, as well as markers of cell line stability. At present Russia has no practical experience in BCP quality evaluation. The aim of the study was to substantiate methodological approaches to authentication of cell lines used in BCPs as illustrated by quality evaluation of the DF-2 model cell line using test methods that allow for characterisation of the morphological, genetic, immunophenotypic, and cytogenetic profile of the cell line. Materials and methods: the study analysed the DF-2 cell line — human dermal fibroblasts (mesenchymal stem cells) obtained from the Institute of Cytology of the Russian Academy of Sciences (St. Petersburg). The following analytical test methods were used in the study: morphological analysis; flow cytometry for immunophenotyping of the DF-2 model cell line; short tandem repeats for creating an allelic profile of the model cell line; cytogenetic analysis — differential DAPI staining of metaphase chromosomes. Results: the paper summarises methodological approaches to identification testing of medicines containing living human cells (BCP analogues) currently used in international practice, and presents the results of authentication of the model cell line. Conclusions: methods used for BCP identification testing should ensure unambiguous authentication of the cell line according to its specification. The study performed helped to work out the procedure of authentication of a model cell line.На каждый разработанный биомедицинский клеточный продукт (БМКП), прошедший доклинические исследования, производитель (разработчик) составляет спецификацию, которая входит в состав регистрационного досье при подаче заявления на государственную регистрацию БМКП. В соответствии с Приказом Министерства здравоохранения Российской Федерации от 19 января 2017 г. № 14н «Об утверждении формы спецификации на биомедицинский клеточный продукт» спецификация должна содержать сведения об идентичности (подлинности) клеточной линии, входящей в состав БМКП, которая включает: морфологические характеристики, экспрессию специфических маркеров, экспрессию специфических генов, экспрессию специфических белков, а также маркеры стабильности клеточной линии. В Российской Федерации на сегодняшний день отсутствует практический опыт проведения экспертизы качества БМКП. Цель работы: обоснование методических подходов к определению идентичности (подлинности) клеточных линий, входящих в состав БМКП, в рамках экспертизы качества на модельной клеточной линии DF-2 при использовании методов, позволяющих характеризовать морфологический, генетический, иммунофенотипический и цитогенетический профиль клеточной линии. Материалы и методы: объектом исследования была клеточная линия DF-2 — дермальные фибробласты человека (мезенхимные стволовые клетки) — получена из Института цитологии РАН (Санкт-Петербург). В работе использовали следующие методы анализа: морфологический анализ; метод проточной цитометрии для иммунофенотипирования модельной клеточной линии DF-2; метод коротких тандемных повторов для построения аллельного профиля модельной клеточной линии; цитогенетическое исследование — DAPI-дифференциальное окрашивание метафазных хромосом. Результаты: в статье представлены методические подходы к определению подлинности препаратов, содержащих жизнеспособные клетки человека (аналогов БМКП), используемые в мировой практике, а также представлены результаты экспериментального определения показателя «Идентичность (подлинность)» на модельной клеточной линии. Выводы: методы оценки подлинности БМКП должны гарантировать однозначную идентификацию клеточной линии в соответствии с представленной спецификацией. В результате проведенных исследований отработана процедура экспертной оценки идентичности (подлинности) модельной клеточной линии

Разработка и изучение отраслевого стандартного образца активности вакцины против краснухи

Presents information on 1st series of branch standard sample to characterization the quality of the candidate of branch standard sample tested for performance evaluation: specific activity of authenticity, a description of sterility, presence of mycoplasma, loss on drying, pH, filling accuracy, the residual oxygen content in the vials. Attested feature of the new series of the standard sample is a specific activity, because the purpose of the of branch reference standard activity live Rubella vaccine is the suitability of the results of determining the specific activity of the Rubella virus in vaccines. Indicator specific activity of the candidate in the of branch reference standard was assessed by interlaboratory studies compared to current 1st standard sample of the enterprise and 1st International Reference Reagent For Rubella (Live) NIBSC-91/688. Certified value of the index is set «Specific activity of branch reference standard activity for rubella (4,63±0,50) lgCCE50/0,5 ml. Shelf-life stated by using test accelerated the degradation is not less than at minus 20°C.Представлены материалы по аттестации первой серии отраслевого стандартного образца (ОСО) активности вакцины против краснухи. Для характеристики качества кандидата в ОСО проведены испытания по оценке показателей: специфическая активность, подлинность, описание, стерильность, присутствие микоплазм, потеря в массе при высушивании, рН, точность наполнения, остаточное содержание кислорода в ампулах. Аттестуемой характеристикой стандартного образца является специфическая активность. Назначение ОСО активности вакцины против краснухи - это оценка приемлемости результатов определения активности вируса краснухи в вакцинах. Показатель «Специфическая активность» кандидата в ОСО оценивали по результатам межлабораторных исследований в сравнении со стандартным образцом предприятия и международным стандартом: 1st International Reference Reagent For Rubella (Live) NIBSC-91/688. Установлено аттестованное значение показателя «Специфическая активность» ОСО активности вакцины против краснухи: (4,63±0,50)lg ТЦД50/0,5 мл. Срок годности, установленный с помощью теста ускоренного старения, при условии хранения при минус 20°С, - не менее 5 лет. Результаты мониторинга стабильности ОСО подтверждают его стабильность за период наблюдения

Present Status of the Anthrax Pathogen Immunodiagnosis

Analysis of the recent domestic and foreign publications concerning the problems of anthrax immunodiagnosis is presented in the current review. The major achievements in the development of the procedures to detect Bacillus anthracis and its antigens using various immunodiagnostic assays are briefly characterized. The most important problems are discussed in connection with the efforts to increase the efficacy of the modern immunodiagnostic kits and their introduction into practice

Current State of Tularemia Immunodiagnostics

This review is devoted to the analysis of the main achievements of the Russian and foreign scientists in the sphere of development of immunodiagnostic methods for detection of Francisella tularensis and specific serum antibodies. The most important problems concerning perspectives of constructing of the modern effective test-systems for tularemia immunodiagnostics are discussed

The experimental correction of the dysbacteriosis by probiotics

In vivo, the obtained evidences were received to necessitate the performance of the standard preclinical research of different dosages of the probiotics in experimental model of the probiotics treatment efficiency study in the case of dysbacteriosis correction. The use of different commercial probiotics in the experimental disbiosis lead to various results of the corrections of intestinal microflora balance: to the increasing of normoflora without the correction of potentially harmful organisms in case of using the normoflora medication; to the increasing of lactose-positive E.coli, lactobacteria, without the bifidobacteria level shifting and to the elimination of fungi and staphylococcus in case of the biosporin. Bactisubtil didn't restore the normoflora and didn't correct the level of the fungi and staphylococcus